TOTAL CONNECTED

HEALTHCARE MARKET

ESTIMATED TO REACH

$59 BILLION

BY 2020¹

CHRONIC CONDITIONS

COST THE US

MORE THAN

$1 TRILLION

ANNUALLY²

HEART DISEASE
& STROKE

ARE THE LEADING CAUSES OF
DEATH IN THE US3

TOTAL CONNECTED

HEALTHCARE MARKET

ESTIMATED TO REACH

$59 BILLION

BY 2020'

TOTAL CONNECTED

HEALTHCARE MARKET

ESTIMATED TO REACH

$59 BILLION

BY 2020'

·

Bioflux is a medical-grade device that actively monitors a patient’s ECG in real time.

·

Bioflux constantly collects and complies data on the device and uploads to the cloud.

·

Bioflux analyzes both device and cloud data in real time in order to support emergency response and physician diagnosis.

·

Bioflux enhances physician workflow by providing physicians with a summary report that facilitates diagnosis.

·

Together with Biotricity’s proprietary software, highly customizable reports, and 24/7 monitoring center, the Bioflux system is a complete solution for remote cardiac monitoring that merges seamlessly with physicians’ existing platforms and workflows.

FETAL ECG

MONITORING

COPD

MONITORING

SLEEP ANEA

MONITORING

SLEEP ANEA

MONITORING

Fetal monitoring analysis market is expected to reach $2.81 billion BY 2022⁴

COPD and Asthma devices market is expected to reach $41.3 Million by 2022⁵

Sleep monitoring devises market is expected to reach $5.3 billion BY 2020⁶

Diabetes glucose monitoring is expected to reach $26 billion by 2021⁷

INVESTMENT CATALYSTS

STRATEGY

RECENT HIGHLIGHTS

·

Company announced the addition of Artificial Intelligence (AI) to its Remote Patient Monitoring (RPM) platform

·

Biotricity expands R&D efforts with push into AI

·

Announced expansion of Bioflux sales force and pilot sites Successfully raised approximately $2.5 million in a registered direct offering

·

Biotricity achieves FDA 51O(k) clearance for Bioflux

·

Disruptive business model that is ideal for physicians: simplifies billing, reduces costs, helps with recurring revenue

·

Remote patient monitoring products are ideal solutions for underserved markets that have growing needs in multiple areas of healthcare data to maximize detection, accuracy and improve learning

PARTNERSHIP

KEY GROWTH DRIVERS

·

Biotrocity has both strategic partnerships as well as research & development partnerships with leading companies

·

AT&T will provide network connectivity for Biotricity’s remote monitoring, lot-connected solutions

·

Global to Local will build solutions that provide outcome measurements for chronic disease patients in underserved populations

·

Other partners include: University of Calgary, Alberta Health Services, Providence Enterprise, Canada NRC CNRC

Bioticity, Inc.

Investor Relations Contact:

275 Shoreline Drive, Suite 150

1.800.951.3348

Redwood City, CA 94065

investors@biotricity.com

1.800.590.4155

www.biotricity.com

5.

Technology/Value Creation — proprietary remote patient monitoring platform will be leveraged across a spectrum of healthcare industries, providing ideal solutions to doctors and patients.  Biotricity’s Bioflux is in the process of entering the marketplace and plans are already underway to pipeline new solutions across a spectrum of health applications.

Market Opportunity — the connected health market is growing at a 33% CAGR and is expected to reach $59 billion by 20201.  The Company has the potential to help millions who suffer from CVD, diabetes, sleep apnea, COPD, and fetal monitoring.

3.

Disruptive Business Model — provides key benefits for physicians: enables them to bill directly, no upfront costs, recurring revenue stream with high margins, turn-key solutions, and bill code integration.

4.

Management Team — is comprised of leaders with expertise in wireless communications, electronics, remote devices, medical devices, cardiology and more.  The advisory board is made up of highly distinguished doctors and healthcare experts as well as C-level executives at leading institutions.

5.

Bioflux — achieved 510(k) clearance with the U.S. Food and Drug Administration FDA.  Expected to be released into the market in Q1 with revenue generated by mid-2018.

1.

MarketsandMarkets

2.

RAND

3.

CDC Foundation

4.

Zion Market Research

5.

MarketsandMarkets

6.

MarketsandMarkets

7.

Allied Market Research

DISCLAIMER: Any statements contained in this fact sheet that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (H), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this fact sheet.